<DOC>
	<DOCNO>NCT03103932</DOCNO>
	<brief_summary>This multi-centre , single blind , randomize study . Patients admit hospital acute decompensated heart failure randomize biomarker guide discharge algorithm v usual care 2:1 ratio . NTproBNP biomarkers measure within 24 hour admission . The NTproBNP result use stratify participant randomize biomarker guide group lower medium high risk pathway . Biomarkers repeat 2-3 day prior discharge . Specific care pathway follow low risk medium-higher risk group . Biomarkers repeat 30 day post discharge . Participants follow phone call 3 month return follow visit 6 month post discharge outcome evaluation .</brief_summary>
	<brief_title>Biomarker Guided Discharge Heart Failure Patients</brief_title>
	<detailed_description>Care Pathways : Usual care : Participants treat heart failure symptom usual participate institution . NTproBNP result reveal care provider . NTproBNP level participant randomize biomarker guide discharge algorithm post participant 's medical record . The result use care provider decision make accord predetermine care pathway . Lower risk group : Participants 's admission NTproBNP 3,000 pg/ml place low risk group . Discharge plan start within 24 hour hospital admission . Symptoms treat aggressively . If NTproBNP level drop 1,500 pg/ml Day 2-3 , participant discharge home . If NTproBNP level drop 1,500 pg/ml , participant continue treatment another day two discharge home medically stabilize . Medium-higher risk group : Participants 's admission NTproBNP 3,000 pg/ml place medium-higher risk group . Symptoms treat aggressively . If NTproBNP level drop 3,000 pg/ml Day 2-3 , participant follow low risk pathway discharge . If NTproBNP level remain 3,000 pg/ml , aggressive treatment symptom continue . Biomarkers repeat Day 6-7 . If NTproBNP level drop least 30 % admission participant medically stabilize , participant discharge home . If NTproBNP level drop least 30 % admission , treatment continue participant medically stabilize . This last group discharge home telehealth daily monitoring . All participant complete Quality Life questionnaire admission 30 day post discharge follow .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients admit hospital primary diagnosis acute decompensated heart failure , compatible modify Framingham criterion Patient unable provide blood sample participate followup Patient end stage organ failure Kidney : creatinine &gt; 350 μmol/L Estimated GFR ≤15 ml/min Liver dysfunction : liver function test &gt; 2.5 time normal Lungs : pulmonary FEV1 &lt; 50 % predict Patient require intubation Patient admission NTproBNP measurement &gt; 30,000 pg/ml Patient list heart transplant , admit specifically transplant workup Patient cardiogenic shock Patient life expectancy le 6 month , major comorbidities new stroke , cancer , pneumonia , serious life threaten illness Patient condition make difficult discharge hospital fall wait long term care bed Any significant disease disorder , opinion Investigator , may either put patient risk participation trial , may bias result trial , patient 's ability participate trial Patient participate another research trial involve investigational product past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>biomarkers</keyword>
	<keyword>heart failure</keyword>
	<keyword>hospital admission</keyword>
</DOC>